6	CD	6	6	6	N	O
.	.	.	.	.	N	O

ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
label	NN	label	label	label	N	O
:	:	:	:	:	N	O

Cytokine	NNP	cytokine	cytokine	cytokin	N	B-AdverseReaction
Release	NNP	release	release	releas	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

Neurological	JJ	neurological	neurological	neurolog	N	B-AdverseReaction
Toxicities	NNS	toxicities	toxicity	toxic	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O

Infections	NNS	infections	infection	infect	N	B-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

Tumor	NNP	tumor	tumor	tumor	N	B-AdverseReaction
Lysis	NNP	lysis	lysis	lysi	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
Febrile	NNP	febrile	febrile	febril	N	B-AdverseReaction
Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O

Effects	NNS	effects	effect	effect	N	B-AdverseReaction
on	IN	on	on	on	N	I-AdverseReaction
Ability	NNP	ability	ability	abil	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
Drive	NNP	drive	drive	drive	N	I-AdverseReaction
and	CC	and	and	and	N	O
Use	NNP	use	use	use	N	I-AdverseReaction
Machines	NNP	machines	machine	machin	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)]	NN	)]	)]	)]	N	O

Elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
Liver	NNP	liver	liver	liver	N	I-AdverseReaction
Enzymes	NNP	enzymes	enzyme	enzym	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)]	NN	)]	)]	)]	N	O

Leukoencephalopathy	JJ	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)]	NN	)]	)]	)]	N	O

Preparation	NN	preparation	preparation	prepar	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
Errors	NNP	errors	error	error	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)]	NN	)]	)]	)]	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
pyrexia	JJ	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O

:	:	:	:	:	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Amgen	NNP	amgen	amgen	amgen	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
77	CD	77	77	77	N	O
-	:	-	-	-	N	O
AMGEN	NNP	amgen	amgen	amgen	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
772	CD	772	772	772	N	O
-	:	-	-	-	N	O
6436	CD	6436	6436	6436	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
section	NN	section	section	section	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
212	CD	212	212	212	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
relapsed	JJ	relapsed	relapsed	relaps	N	O
or	CC	or	or	or	N	O
refractory	JJ	refractory	refractory	refractori	N	O
ALL	DT	all	all	all	N	O
received	VBD	received	received	receiv	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
28	CD	28	28	28	N	O
mcg	NNS	mcg	mcg	mcg	N	O
day	NN	day	day	day	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
received	VBN	received	received	receiv	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
population	NN	population	population	popul	N	O
was	VBD	was	wa	wa	N	O
37	CD	37	37	37	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
18	CD	18	18	18	N	O
to	TO	to	to	to	N	O
79	CD	79	79	79	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
63%	CD	63%	63%	63%	N	O
were	VBD	were	were	were	N	O
male	NN	male	male	male	N	O
,	,	,	,	,	N	O
79%	CD	79%	79%	79%	N	O
were	VBD	were	were	were	N	O
White	NNP	white	white	white	N	O
,	,	,	,	,	N	O
3%	CD	3%	3%	3%	N	O
were	VBD	were	were	were	N	O
Asian	JJ	asian	asian	asian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
3%	CD	3%	3%	3%	N	O
were	VBD	were	were	were	N	O
Black	NNP	black	black	black	N	O
or	CC	or	or	or	N	O
African	JJ	african	african	african	N	O
American	NNP	american	american	american	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
pyrexia	VBN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
(	(	(	(	(	N	O
62%	CD	62%	62%	62%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
(	(	(	(	(	N	O
36%	CD	36%	36%	36%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
23%	CD	23%	23%	23%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
65%	CD	65%	65%	65%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
included	VBD	included	included	includ	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
,	,	,	,	,	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
device	NN	device	device	devic	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
,	,	,	,	,	N	O
encephalopathy	JJ	encephalopathy	encephalopathy	encephalopathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
infection	NN	infection	infection	infect	Y	B-AdverseReaction
,	,	,	,	,	N	O
overdose	RB	overdose	overdose	overdos	Y	B-AdverseReaction
,	,	,	,	,	N	O
confusion	NN	confusion	confusion	confus	Y	B-AdverseReaction
,	,	,	,	,	N	O
Staphylococcal	NNP	staphylococcal	staphylococcal	staphylococc	N	B-AdverseReaction
bacteremia	NN	bacteremia	bacteremia	bacteremia	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
higher	JJR	higher	higher	higher	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
80%	CD	80%	80%	80%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
18%	CD	18%	18%	18%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBD	reported	reported	report	N	O
most	JJS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
as	IN	as	a	as	N	O
the	DT	the	the	the	N	O
reason	NN	reason	reason	reason	N	O
for	IN	for	for	for	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
included	VBD	included	included	includ	N	O
encephalopathy	JJ	encephalopathy	encephalopathy	encephalopathi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
.	.	.	.	.	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
15%	CD	15%	15%	15%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
.	.	.	.	.	N	O

No	DT	no	no	no	N	B-Negation
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
occurred	VBD	occurred	occurred	occur	N	O
on	IN	on	on	on	N	O
treatment	NN	treatment	treatment	treatment	N	O
among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
remission	NN	remission	remission	remiss	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
with	IN	with	with	with	N	O
10%	CD	10%	10%	10%	N	O
incidence	NN	incidence	incidence	incid	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
grade	NN	grade	grade	grade	N	O
or	CC	or	or	or	N	O
5%	CD	5%	5%	5%	N	O
incidence	NN	incidence	incidence	incid	N	O
for	IN	for	for	for	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
higher	JJR	higher	higher	higher	N	O
are	VBP	are	are	are	N	O
summarized	VBN	summarized	summarized	summar	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
With	IN	with	with	with	N	O
10%	CD	10%	10%	10%	N	O
Incidence	NN	incidence	incidence	incid	N	O
for	IN	for	for	for	N	O
Any	NNP	any	any	ani	N	O
Grade	NNP	grade	grade	grade	N	O
or	CC	or	or	or	N	O
5%	CD	5%	5%	5%	N	O
Incidence	NN	incidence	incidence	incid	N	O
for	IN	for	for	for	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
Higher	JJR	higher	higher	higher	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
212	CD	212	212	212	N	O
)	)	)	)	)	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Any	NNP	any	any	ani	N	O
GradeGrading	NNP	gradegrading	gradegrading	gradegrad	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
NCI	NNP	nci	nci	nci	N	O
Common	NNP	common	common	common	N	O
Terminology	NNP	terminology	terminology	terminolog	N	O
Criteria	NNP	criteria	criterion	criteria	N	O
for	IN	for	for	for	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Events	NNP	events	event	event	N	O
(	(	(	(	(	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
)	)	)	)	)	N	O
version	NN	version	version	version	N	O
4.0	CD	4.0	4.0	4.0	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBZ	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
Higher	JJR	higher	higher	higher	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Blood	NN	blood	blood	blood	N	O

and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
Febrile	NNP	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
Anemia	NNP	anemia	anemia	anemia	Y	B-AdverseReaction
Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
Leukopenia	NNP	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
251816119	CD	251816119	251816119	251816119	N	O
23131588	CD	23131588	23131588	23131588	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
Nausea	NNP	nausea	nausea	nausea	Y	B-AdverseReaction
Constipation	NNP	constipation	constipation	constip	Y	B-AdverseReaction
DiarrheaDiarrhea	NNP	diarrheadiarrhea	diarrheadiarrhea	diarrheadiarrhea	N	B-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O
colitis	NN	colitis	colitis	coliti	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
enteritis	NN	enteritis	enteritis	enter	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
neutropenic	JJ	neutropenic	neutropenic	neutropen	N	B-AdverseReaction
colitis	NN	colitis	colitis	coliti	Y	I-AdverseReaction
.	.	.	.	.	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
2520201513	CD	2520201513	2520201513	2520201513	N	O
0	CD	0	0	0	N	O
1120	CD	1120	1120	1120	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NNP	edema	edema	edema	Y	I-AdverseReaction
Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
Chills	NNP	chills	chill	chill	Y	B-AdverseReaction
Chest	NNP	chest	chest	chest	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
6225171511	CD	6225171511	6225171511	6225171511	N	O
7	CD	7	7	7	N	O
1101	CD	1101	1101	1101	N	O

Immune	NNP	immune	immune	immun	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
Cytokine	NNP	cytokine	cytokine	cytokin	N	B-AdverseReaction
release	NN	release	release	releas	N	I-AdverseReaction
syndrome	VBD	syndrome	syndrome	syndrom	N	I-AdverseReaction
11	CD	11	11	11	N	O
1	CD	1	1	1	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
Other	JJ	other	other	other	N	O
pathogen	JJ	pathogen	pathogen	pathogen	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
Bacterial	JJ	bacterial	bacterial	bacteri	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
Fungal	NNP	fungal	fungal	fungal	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
Viral	NNP	viral	viral	viral	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
Pneumonia	NNP	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
Sepsis	NNP	sepsis	sepsis	sepsi	Y	B-AdverseReaction
4419151397	CD	4419151397	4419151397	4419151397	N	O
25127486	CD	25127486	25127486	25127486	N	O

Investigations	NNS	investigations	investigation	investig	N	O
Increased	VBD	increased	increased	increas	N	B-AdverseReaction
alanine	JJ	alanine	alanine	alanin	N	I-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
Increased	VBD	increased	increased	increas	N	B-AdverseReaction
aspartate	JJ	aspartate	aspartate	aspart	N	I-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
Increased	VBD	increased	increased	increas	N	B-AdverseReaction
weight	VBD	weight	weight	weight	Y	I-AdverseReaction
121111	CD	121111	121111	121111	N	O
640	CD	640	640	640	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O
Hypokalemia	NNP	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
Hypomagnesemia	NNP	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	B-AdverseReaction
Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
appetite	JJ	appetite	appetite	appetit	N	I-AdverseReaction
Hypophosphatemia	NNP	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
231211106	CD	231211106	231211106	231211106	N	O
60735	CD	60735	60735	60735	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
Back	RP	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
Bone	NNP	bone	bone	bone	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
14121110	CD	14121110	14121110	14121110	N	O
2132	CD	2132	2132	2132	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
TremorTremor	NNP	tremortremor	tremortremor	tremortremor	N	B-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O
resting	NN	resting	resting	rest	N	B-AdverseReaction
tremor	NN	tremor	tremor	tremor	Y	I-AdverseReaction
and	CC	and	and	and	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
.	.	.	.	.	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
362014	CD	362014	362014	362014	N	O
31	CD	31	31	31	N	O
1	CD	1	1	1	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O
Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
15	CD	15	15	15	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
DyspneaDyspnea	NNP	dyspneadyspnea	dyspneadyspnea	dyspneadyspnea	N	B-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O
acute	NN	acute	acute	acut	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
bronchial	JJ	bronchial	bronchial	bronchial	N	B-AdverseReaction
hyperactivity	NN	hyperactivity	hyperactivity	hyperact	Y	I-AdverseReaction
,	,	,	,	,	N	O
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	JJ	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
exertional	JJ	exertional	exertional	exert	N	I-AdverseReaction
,	,	,	,	,	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
distress	NN	distress	distress	distress	N	I-AdverseReaction
,	,	,	,	,	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
wheezing	NN	wheezing	wheezing	wheez	Y	B-AdverseReaction
.	.	.	.	.	N	O

1915	CD	1915	1915	1915	N	O
05	CD	05	05	05	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
RashRash	NNP	rashrash	rashrash	rashrash	N	B-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
erythematous	JJ	erythematous	erythematous	erythemat	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
,	,	,	,	,	N	O
generalized	VBN	generalized	generalized	gener	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
,	,	,	,	,	N	O
macular	JJ	macular	macular	macular	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
,	,	,	,	,	N	O
maculo	SYM	maculo	maculo	maculo	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
papular	JJ	papular	papular	papular	N	I-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
,	,	,	,	,	N	O
papular	JJ	papular	papular	papular	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vesicular	JJ	vesicular	vesicular	vesicular	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
.	.	.	.	.	N	O

21	CD	21	21	21	N	O
2	CD	2	2	2	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O
Hypotension	NNP	hypotension	hypotension	hypotens	Y	B-AdverseReaction
Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
118	CD	118	118	118	N	O
25	CD	25	25	25	N	O

Additional	NNP	additional	additional	addit	N	O
important	JJ	important	important	import	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
meet	VB	meet	meet	meet	N	O
the	DT	the	the	the	N	O
threshold	NN	threshold	threshold	threshold	N	O
criteria	NN	criteria	criterion	criteria	N	O
for	IN	for	for	for	N	O
inclusion	NN	inclusion	inclusion	inclus	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O

Blood	NN	blood	blood	blood	N	O

and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
leukocytosis	NN	leukocytosis	leukocytosis	leukocytosi	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
lymphopenia	NN	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
:	:	:	:	:	N	O
edema	NN	edema	edema	edema	Y	B-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O

Immune	NNP	immune	immune	immun	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
cytokine	NN	cytokine	cytokine	cytokin	N	B-AdverseReaction
storm	NN	storm	storm	storm	N	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Investigations	NNS	investigations	investigation	investig	N	O
:	:	:	:	:	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
immunoglobulins	NNS	immunoglobulins	immunoglobulin	immunoglobulin	Y	I-AdverseReaction
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
gamma	SYM	gamma	gamma	gamma	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
glutamyl	NN	glutamyl	glutamyl	glutamyl	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
transferase	NN	transferase	transferase	transferas	N	I-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
liver	NN	liver	liver	liver	N	I-AdverseReaction
enzymes	NNS	enzymes	enzyme	enzym	N	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
tumor	NN	tumor	tumor	tumor	N	B-AdverseReaction
lysis	NN	lysis	lysis	lysi	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hypoalbuminemia	NN	hypoalbuminemia	hypoalbuminemia	hypoalbuminemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
encephalopathy	NN	encephalopathy	encephalopathy	encephalopathi	Y	B-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	B-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
aphasia	NN	aphasia	aphasia	aphasia	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
convulsion	NN	convulsion	convulsion	convuls	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
memory	JJ	memory	memory	memori	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
cognitive	JJ	cognitive	cognitive	cognit	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
speech	JJ	speech	speech	speech	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
confusion	NN	confusion	confusion	confus	Y	B-AdverseReaction
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
disorientation	NN	disorientation	disorientation	disorient	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
capillary	JJ	capillary	capillary	capillari	N	B-AdverseReaction
leak	NN	leak	leak	leak	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
treatment	NN	treatment	treatment	treatment	N	O
were	VBD	were	were	were	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
all	DT	all	all	all	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
proteins	NNS	proteins	protein	protein	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
potential	JJ	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O
of	IN	of	of	of	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
using	VBG	using	using	use	N	O
either	CC	either	either	either	N	O
an	DT	an	an	an	N	O
electrochemiluminescence	NN	electrochemiluminescence	electrochemiluminescence	electrochemiluminesc	N	O
detection	NN	detection	detection	detect	N	O
technology	NN	technology	technology	technolog	N	O
(	(	(	(	(	N	O
ECL	NNP	ecl	ecl	ecl	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
an	DT	an	an	an	N	O
enzyme	JJ	enzyme	enzyme	enzym	N	O
-	:	-	-	-	N	O
linked	VBN	linked	linked	link	N	O
immunosorbent	JJ	immunosorbent	immunosorbent	immunosorb	N	O
assay	NN	assay	assay	assay	N	O
(	(	(	(	(	N	O
ELISA	NNP	elisa	elisa	elisa	Y	O
)	)	)	)	)	N	O
screening	VBG	screening	screening	screen	N	O
immunoassay	NN	immunoassay	immunoassay	immunoassay	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
detection	NN	detection	detection	detect	N	O
of	IN	of	of	of	N	O
binding	VBG	binding	binding	bind	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
blinatumomab	NN	blinatumomab	blinatumomab	blinatumomab	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
sera	NN	sera	serum	sera	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
screening	NN	screening	screening	screen	N	O
immunoassay	NN	immunoassay	immunoassay	immunoassay	N	O
,	,	,	,	,	N	O
an	DT	an	an	an	N	O
in	IN	in	in	in	N	O
vitro	JJ	vitro	vitro	vitro	N	O
biological	JJ	biological	biological	biolog	N	O
assay	NN	assay	assay	assay	N	O
was	VBD	was	wa	wa	N	O
performed	VBN	performed	performed	perform	N	O
to	TO	to	to	to	N	O
detect	VB	detect	detect	detect	N	O
neutralizing	JJ	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
binding	VBG	binding	binding	bind	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
blinatumomab	NN	blinatumomab	blinatumomab	blinatumomab	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
binding	VBG	binding	binding	bind	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
also	RB	also	also	also	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
blinatumomab	NN	blinatumomab	blinatumomab	blinatumomab	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O

Anti	NNP	anti	anti	anti	N	O
-	:	-	-	-	N	O
blinatumomab	NN	blinatumomab	blinatumomab	blinatumomab	N	O
antibody	NN	antibody	antibody	antibodi	N	O
formation	NN	formation	formation	format	N	O
may	MD	may	may	may	N	O
affect	VB	affect	affect	affect	N	O
pharmacokinetics	NNS	pharmacokinetics	pharmacokinetics	pharmacokinet	N	O
of	IN	of	of	of	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
association	NN	association	association	associ	N	O
was	VBD	was	wa	wa	N	O
seen	VBN	seen	seen	seen	N	O
between	IN	between	between	between	N	O
antibody	NN	antibody	antibody	antibodi	N	O
development	NN	development	development	develop	N	O
and	CC	and	and	and	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
formation	NN	formation	formation	format	N	O
of	IN	of	of	of	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
blinatumomab	NN	blinatumomab	blinatumomab	blinatumomab	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
effect	NN	effect	effect	effect	N	O
is	VBZ	is	is	is	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
contact	JJ	contact	contact	contact	N	O
Amgen	NNP	amgen	amgen	amgen	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
77	CD	77	77	77	N	O
-	:	-	-	-	N	O
AMGEN	NNP	amgen	amgen	amgen	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
772	CD	772	772	772	N	O
-	:	-	-	-	N	O
6436	CD	6436	6436	6436	N	O
)	)	)	)	)	N	O
to	TO	to	to	to	N	O
discuss	VB	discuss	discus	discuss	N	O
antibody	NN	antibody	antibody	antibodi	N	O
testing	VBG	testing	testing	test	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
detection	NN	detection	detection	detect	N	O
of	IN	of	of	of	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
blinatumomab	NN	blinatumomab	blinatumomab	blinatumomab	N	O
antibody	NN	antibody	antibody	antibodi	N	O
formation	NN	formation	formation	format	N	O
is	VBZ	is	is	is	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
assay	NN	assay	assay	assay	N	O
.	.	.	.	.	N	O

Additionally	RB	additionally	additionally	addit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
observed	JJ	observed	observed	observ	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibody	NN	antibody	antibody	antibodi	N	O
)	)	)	)	)	N	O
positivity	NN	positivity	positivity	posit	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
assay	NN	assay	assay	assay	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
influenced	VBN	influenced	influenced	influenc	N	O
by	IN	by	by	by	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
assay	JJ	assay	assay	assay	N	O
methodology	NN	methodology	methodology	methodolog	N	O
,	,	,	,	,	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
comparison	NN	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
blinatumomab	VB	blinatumomab	blinatumomab	blinatumomab	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
misleading	VBG	misleading	misleading	mislead	N	O
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
CYTOKINE	NNP	cytokine	cytokine	cytokin	N	B-AdverseReaction
RELEASE	NNP	release	release	releas	N	I-AdverseReaction
SYNDROME	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
and	CC	and	and	and	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
NEUROLOGICAL	NNP	neurological	neurological	neurolog	N	B-AdverseReaction
TOXICITIES	NNP	toxicities	toxicity	toxic	N	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
CYTOKINE	NNP	cytokine	cytokine	cytokin	N	B-AdverseReaction
RELEASE	NNP	release	release	releas	N	I-AdverseReaction
SYNDROME	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
and	CC	and	and	and	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
NEUROLOGICAL	NNP	neurological	neurological	neurolog	N	B-AdverseReaction
TOXICITIES	NNP	toxicities	toxicity	toxic	N	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Cytokine	NNP	cytokine	cytokine	cytokin	N	B-AdverseReaction
Release	NNP	release	release	releas	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
CRS	NNP	crs	cr	cr	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
or	CC	or	or	or	N	O
fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
.	.	.	.	.	N	O

Interrupt	NNP	interrupt	interrupt	interrupt	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
as	IN	as	a	as	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Neurological	JJ	neurological	neurological	neurolog	N	B-AdverseReaction
toxicities	NNS	toxicities	toxicity	toxic	N	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
severe	JJ	severe	severe	sever	N	B-Severity
,	,	,	,	,	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
.	.	.	.	.	N	O

Interrupt	NNP	interrupt	interrupt	interrupt	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
as	IN	as	a	as	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
CYTOKINE	NNP	cytokine	cytokine	cytokin	N	B-AdverseReaction
RELEASE	NNP	release	release	releas	N	I-AdverseReaction
SYNDROME	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
and	CC	and	and	and	N	O
NEUROLOGICAL	NNP	neurological	neurological	neurolog	N	B-AdverseReaction
TOXICITIES	NNP	toxicities	toxicity	toxic	N	I-AdverseReaction
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Cytokine	NNP	cytokine	cytokine	cytokin	N	B-AdverseReaction
Release	NNP	release	release	releas	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
CRS	NNP	crs	cr	cr	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
or	CC	or	or	or	N	O
fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
.	.	.	.	.	N	O

Interrupt	NNP	interrupt	interrupt	interrupt	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
as	IN	as	a	as	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	FW	\n	\n	\n	N	O
Neurological	JJ	neurological	neurological	neurolog	N	B-AdverseReaction
toxicities	NNS	toxicities	toxicity	toxic	N	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
severe	JJ	severe	severe	sever	N	B-Severity
,	,	,	,	,	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
.	.	.	.	.	N	O

Interrupt	NNP	interrupt	interrupt	interrupt	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
as	IN	as	a	as	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
.	.	.	.	.	N	O

WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Infections	NNS	infections	infection	infect	N	B-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
appropriately	RB	appropriately	appropriately	appropri	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Effects	NNS	effects	effect	effect	N	B-AdverseReaction
on	IN	on	on	on	N	I-AdverseReaction
Ability	NNP	ability	ability	abil	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
Drive	NNP	drive	drive	drive	N	I-AdverseReaction
and	CC	and	and	and	N	O
Use	NNP	use	use	use	N	I-AdverseReaction
Machines	NNS	machines	machine	machin	N	I-AdverseReaction
:	:	:	:	:	N	O
Advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
refrain	VB	refrain	refrain	refrain	N	O
from	IN	from	from	from	N	O
driving	VBG	driving	driving	drive	N	O
and	CC	and	and	and	N	O
engaging	VBG	engaging	engaging	engag	N	O
in	IN	in	in	in	N	O
hazardous	JJ	hazardous	hazardous	hazard	N	O
occupations	NNS	occupations	occupation	occup	N	O
or	CC	or	or	or	N	O
activities	NNS	activities	activity	activ	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
operating	VBG	operating	operating	oper	N	O
heavy	NN	heavy	heavy	heavi	N	O
or	CC	or	or	or	N	O
potentially	RB	potentially	potentially	potenti	N	O
dangerous	JJ	dangerous	dangerous	danger	N	O
machinery	NN	machinery	machinery	machineri	N	O
while	IN	while	while	while	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
is	VBZ	is	is	is	N	O
being	VBG	being	being	be	N	O
administered	VBN	administered	administered	administ	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Preparation	NN	preparation	preparation	prepar	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
Errors	NNS	errors	error	error	N	O
:	:	:	:	:	N	O
Strictly	RB	strictly	strictly	strictli	N	O
follow	VBP	follow	follow	follow	N	O
instructions	NNS	instructions	instruction	instruct	N	O
for	IN	for	for	for	N	O
preparation	NN	preparation	preparation	prepar	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
admixing	VBG	admixing	admixing	admix	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Cytokine	NN	cytokine	cytokine	cytokin	N	O

Release	NNP	release	release	releas	N	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O

Cytokine	NNP	cytokine	cytokine	cytokin	N	B-AdverseReaction
Release	NNP	release	release	releas	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
CRS	NNP	crs	cr	cr	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
or	CC	or	or	or	N	O
fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
.	.	.	.	.	N	O

Infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
infusion	NN	infusion	infusion	infus	Y	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
clinically	RB	clinically	clinically	clinic	N	O
indistinguishable	JJ	indistinguishable	indistinguishable	indistinguish	N	O
from	IN	from	from	from	N	O
manifestations	NNS	manifestations	manifestation	manifest	N	O
of	IN	of	of	of	N	O
CRS	NNP	crs	cr	cr	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
CRS	NNP	crs	cr	cr	N	B-AdverseReaction
included	VBD	included	included	includ	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
alanine	JJ	alanine	alanine	alanin	N	I-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
aspartate	JJ	aspartate	aspartate	aspart	N	I-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
total	JJ	total	total	total	N	I-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
;	:	;	;	;	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
infrequently	RB	infrequently	infrequently	infrequ	N	O
led	VBN	led	led	led	N	O
to	TO	to	to	to	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
.	.	.	.	.	N	O

Life	NNP	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
or	CC	or	or	or	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
CRS	NNP	crs	cr	cr	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
infrequently	RB	infrequently	infrequently	infrequ	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
some	DT	some	some	some	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
disseminated	VBD	disseminated	disseminated	dissemin	N	B-AdverseReaction
intravascular	JJ	intravascular	intravascular	intravascular	N	I-AdverseReaction
coagulation	NN	coagulation	coagulation	coagul	N	I-AdverseReaction
(	(	(	(	(	N	O
DIC	NNP	dic	dic	dic	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
capillary	JJ	capillary	capillary	capillari	N	B-AdverseReaction
leak	NN	leak	leak	leak	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
CLS	NNP	cls	cl	cl	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hemophagocytic	JJ	hemophagocytic	hemophagocytic	hemophagocyt	N	B-AdverseReaction
lymphohistiocytosis	NN	lymphohistiocytosis	lymphohistiocytosis	lymphohistiocytosi	Y	I-AdverseReaction
macrophage	NN	macrophage	macrophage	macrophag	N	B-AdverseReaction
activation	NN	activation	activation	activ	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
HLH	NNP	hlh	hlh	hlh	N	B-AdverseReaction
MAS	NNP	mas	ma	ma	N	B-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
setting	NN	setting	setting	set	N	O
of	IN	of	of	of	N	O
CRS	NNP	crs	cr	cr	N	B-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
closely	RB	closely	closely	close	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

Management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
either	CC	either	either	either	N	O
temporary	JJ	temporary	temporary	temporari	N	O
interruption	NN	interruption	interruption	interrupt	N	O
or	CC	or	or	or	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Neurological	JJ	neurological	neurological	neurolog	N	O
Toxicities	NNS	toxicities	toxicity	toxic	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
neurological	JJ	neurological	neurological	neurolog	N	B-AdverseReaction
toxicities	NNS	toxicities	toxicity	toxic	N	I-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
approximately	RB	approximately	approximately	approxim	N	O
50%	CD	50%	50%	50%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
was	VBD	was	wa	wa	N	O
7	CD	7	7	7	N	O
days	NNS	days	day	day	N	O
.	.	.	.	.	N	O

Grade	VB	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
higher	JJR	higher	higher	higher	N	O
(	(	(	(	(	N	O
severe	JJ	severe	severe	sever	N	B-Severity
,	,	,	,	,	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction
)	)	)	)	)	N	O
neurological	JJ	neurological	neurological	neurolog	N	B-AdverseReaction
toxicities	NNS	toxicities	toxicity	toxic	N	I-AdverseReaction
following	VBG	following	following	follow	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
administration	NN	administration	administration	administr	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
approximately	RB	approximately	approximately	approxim	N	O
15%	CD	15%	15%	15%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
included	VBD	included	included	includ	N	O
encephalopathy	NN	encephalopathy	encephalopathy	encephalopathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
convulsions	NNS	convulsions	convulsion	convuls	Y	B-AdverseReaction
,	,	,	,	,	N	O
speech	NN	speech	speech	speech	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
disturbances	NNS	disturbances	disturbance	disturb	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
consciousness	NN	consciousness	consciousness	conscious	N	I-AdverseReaction
,	,	,	,	,	N	O
confusion	NN	confusion	confusion	confus	Y	B-AdverseReaction
and	CC	and	and	and	N	O
disorientation	NN	disorientation	disorientation	disorient	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
coordination	NN	coordination	coordination	coordin	N	B-AdverseReaction
and	CC	and	and	and	N	O
balance	NN	balance	balance	balanc	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
events	NNS	events	event	event	N	O
resolved	VBN	resolved	resolved	resolv	N	O
following	VBG	following	following	follow	N	O
interruption	NN	interruption	interruption	interrupt	N	O
of	IN	of	of	of	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
some	DT	some	some	some	N	O
resulted	VBD	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
toxicities	NNS	toxicities	toxicity	toxic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
interrupt	NN	interrupt	interrupt	interrupt	N	O
or	CC	or	or	or	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
as	IN	as	a	as	N	O
recommended	JJ	recommended	recommended	recommend	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Infections	NNS	infections	infection	infect	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
bacteremia	NN	bacteremia	bacteremia	bacteremia	Y	B-AdverseReaction
,	,	,	,	,	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
catheter	SYM	catheter	catheter	cathet	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
approximately	RB	approximately	approximately	approxim	N	O
25%	CD	25%	25%	25%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
were	VBD	were	were	were	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
or	CC	or	or	or	N	O
fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

As	IN	as	a	as	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
,	,	,	,	,	N	O
administer	JJ	administer	administer	administ	N	O
prophylactic	JJ	prophylactic	prophylactic	prophylact	Y	O
antibiotics	NNS	antibiotics	antibiotic	antibiot	N	O
and	CC	and	and	and	N	O
employ	JJ	employ	employ	employ	N	O
surveillance	NN	surveillance	surveillance	surveil	N	O
testing	VBG	testing	testing	test	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
appropriately	RB	appropriately	appropriately	appropri	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Tumor	NNP	tumor	tumor	tumor	N	O
Lysis	NNP	lysis	lysis	lysi	N	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O

Tumor	NNP	tumor	tumor	tumor	N	B-AdverseReaction
lysis	NN	lysis	lysis	lysi	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
TLS	NNP	tls	tl	tl	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
or	CC	or	or	or	N	O
fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
.	.	.	.	.	N	O

Appropriate	NNP	appropriate	appropriate	appropri	N	O
prophylactic	JJ	prophylactic	prophylactic	prophylact	Y	O
measures	NNS	measures	measure	measur	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
pretreatment	NN	pretreatment	pretreatment	pretreat	N	O
nontoxic	JJ	nontoxic	nontoxic	nontox	N	O
cytoreduction	NN	cytoreduction	cytoreduction	cytoreduct	N	O
and	CC	and	and	and	N	O
on	IN	on	on	on	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
hydration	NN	hydration	hydration	hydrat	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
prevention	NN	prevention	prevention	prevent	Y	O
of	IN	of	of	of	N	O
TLS	NNP	tls	tl	tl	N	O
during	IN	during	during	dure	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
TLS	NNP	tls	tl	tl	N	O
.	.	.	.	.	N	O

Management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
either	CC	either	either	either	N	O
temporary	JJ	temporary	temporary	temporari	N	O
interruption	NN	interruption	interruption	interrupt	N	O
or	CC	or	or	or	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	O
and	CC	and	and	and	N	O
Febrile	NNP	febrile	febrile	febril	N	O
Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
parameters	NNS	parameters	parameter	paramet	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
not	RB	not	not	not	N	O
limited	JJ	limited	limited	limit	N	O
to	TO	to	to	to	N	O
,	,	,	,	,	N	O
white	JJ	white	white	white	N	O
blood	NN	blood	blood	blood	N	O
cell	NN	cell	cell	cell	N	O
count	NN	count	count	count	N	O
and	CC	and	and	and	N	O
absolute	JJ	absolute	absolute	absolut	N	O
neutrophil	NN	neutrophil	neutrophil	neutrophil	N	O
count	NN	count	count	count	N	O
)	)	)	)	)	N	O
during	IN	during	during	dure	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
infusion	NN	infusion	infusion	infus	Y	O
.	.	.	.	.	N	O

Interrupt	NNP	interrupt	interrupt	interrupt	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
if	IN	if	if	if	N	O
prolonged	VBN	prolonged	prolonged	prolong	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
occurs	VBZ	occurs	occurs	occur	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Effects	NNS	effects	effect	effect	N	O
on	IN	on	on	on	N	O
Ability	NNP	ability	ability	abil	N	O
to	TO	to	to	to	N	O
Drive	NNP	drive	drive	drive	N	O
and	CC	and	and	and	N	O
Use	NNP	use	use	use	N	O
Machines	NNS	machines	machine	machin	N	O

Due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
potential	NN	potential	potential	potenti	N	B-Factor
for	IN	for	for	for	N	O
neurologic	JJ	neurologic	neurologic	neurolog	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
seizures	NNS	seizures	seizure	seizur	Y	B-AdverseReaction
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
loss	NN	loss	loss	loss	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
consciousness	JJ	consciousness	consciousness	conscious	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
refrain	VB	refrain	refrain	refrain	N	O
from	IN	from	from	from	N	O
driving	VBG	driving	driving	drive	N	O
and	CC	and	and	and	N	O
engaging	VBG	engaging	engaging	engag	N	O
in	IN	in	in	in	N	O
hazardous	JJ	hazardous	hazardous	hazard	N	O
occupations	NNS	occupations	occupation	occup	N	O
or	CC	or	or	or	N	O
activities	NNS	activities	activity	activ	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
operating	VBG	operating	operating	oper	N	O
heavy	NN	heavy	heavy	heavi	N	O
or	CC	or	or	or	N	O
potentially	RB	potentially	potentially	potenti	N	O
dangerous	JJ	dangerous	dangerous	danger	N	O
machinery	NN	machinery	machinery	machineri	N	O
while	IN	while	while	while	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
is	VBZ	is	is	is	N	O
being	VBG	being	being	be	N	O
administered	VBN	administered	administered	administ	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Elevated	VBD	elevated	elevated	elev	N	O
Liver	NNP	liver	liver	liver	N	O
Enzymes	NNP	enzymes	enzyme	enzym	N	O

Treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
transient	JJ	transient	transient	transient	N	B-Severity
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
liver	NN	liver	liver	liver	N	I-AdverseReaction
enzymes	NNS	enzymes	enzyme	enzym	N	I-AdverseReaction
.	.	.	.	.	N	O

Although	IN	although	although	although	N	O
the	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
setting	NN	setting	setting	set	N	O
of	IN	of	of	of	N	O
CRS	NNP	crs	cr	cr	N	B-AdverseReaction
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
outside	IN	outside	outside	outsid	N	O
of	IN	of	of	of	N	O
this	DT	this	this	thi	N	O
setting	NN	setting	setting	set	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
was	VBD	was	wa	wa	N	O
15	CD	15	15	15	N	O
days	NNS	days	day	day	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
liver	NN	liver	liver	liver	N	I-AdverseReaction
enzymes	NNS	enzymes	enzyme	enzym	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
approximately	RB	approximately	approximately	approxim	N	O
6%	CD	6%	6%	6%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
outside	IN	outside	outside	outsid	N	B-Negation
the	DT	the	the	the	N	O
setting	NN	setting	setting	set	N	O
of	IN	of	of	of	N	O
CRS	NNP	crs	cr	cr	N	B-AdverseReaction
and	CC	and	and	and	N	O
resulted	VBD	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
alanine	JJ	alanine	alanine	alanin	N	O
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	O
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
aspartate	JJ	aspartate	aspartate	aspart	N	O
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	O
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
gamma	SYM	gamma	gamma	gamma	N	O
-	:	-	-	-	N	O
glutamyl	NN	glutamyl	glutamyl	glutamyl	N	O
transferase	NN	transferase	transferase	transferas	N	O
(	(	(	(	(	N	O
GGT	NNP	ggt	ggt	ggt	Y	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
total	JJ	total	total	total	N	O
blood	NN	blood	blood	blood	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
start	NN	start	start	start	N	O
of	IN	of	of	of	N	O
and	CC	and	and	and	N	O
during	IN	during	during	dure	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Interrupt	NNP	interrupt	interrupt	interrupt	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
transaminases	NNS	transaminases	transaminase	transaminas	Y	O
rise	VBP	rise	rise	rise	N	O
to	TO	to	to	to	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
5	CD	5	5	5	N	O
times	NNS	times	time	time	N	O
the	DT	the	the	the	N	O
upper	JJ	upper	upper	upper	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
normal	JJ	normal	normal	normal	N	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
bilirubin	JJ	bilirubin	bilirubin	bilirubin	Y	O
rises	NNS	rises	rise	rise	N	O
to	TO	to	to	to	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
3	CD	3	3	3	N	O
times	NNS	times	time	time	N	O
the	DT	the	the	the	N	O
upper	JJ	upper	upper	upper	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
normal	JJ	normal	normal	normal	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Leukoencephalopathy	JJ	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	O

Cranial	NNP	cranial	cranial	cranial	N	O
magnetic	JJ	magnetic	magnetic	magnet	N	O
resonance	NN	resonance	resonance	reson	N	O
imaging	NN	imaging	imaging	imag	N	O
(	(	(	(	(	N	O
MRI	NNP	mri	mri	mri	Y	O
)	)	)	)	)	N	O
changes	VBZ	changes	change	chang	N	O
showing	VBG	showing	showing	show	N	O
leukoencephalopathy	NNS	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
prior	JJ	prior	prior	prior	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
cranial	JJ	cranial	cranial	cranial	N	O
irradiation	NN	irradiation	irradiation	irradi	N	O
and	CC	and	and	and	N	O
antileukemic	JJ	antileukemic	antileukemic	antileukem	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
systemic	JJ	systemic	systemic	system	N	O
high	JJ	high	high	high	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
methotrexate	NN	methotrexate	methotrexate	methotrex	N	O
or	CC	or	or	or	N	O
intrathecal	JJ	intrathecal	intrathecal	intrathec	N	O
cytarabine	NN	cytarabine	cytarabine	cytarabin	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
significance	NN	significance	significance	signific	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
imaging	JJ	imaging	imaging	imag	N	O
changes	NNS	changes	change	chang	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Preparation	NNP	preparation	preparation	prepar	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
Errors	NNS	errors	error	error	N	O

Preparation	NN	preparation	preparation	prepar	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
errors	NNS	errors	error	error	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
with	IN	with	with	with	N	O
BLINCYTO	NNP	blincyto	blincyto	blincyto	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Follow	NNP	follow	follow	follow	N	O
instructions	NNS	instructions	instruction	instruct	N	O
for	IN	for	for	for	N	O
preparation	NN	preparation	preparation	prepar	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
admixing	VBG	admixing	admixing	admix	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
strictly	RB	strictly	strictly	strictli	N	O
to	TO	to	to	to	N	O
minimize	VB	minimize	minimize	minim	N	O
medication	NN	medication	medication	medic	N	O
errors	NNS	errors	error	error	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
underdose	JJ	underdose	underdose	underdos	Y	O
and	CC	and	and	and	N	O
overdose	JJ	overdose	overdose	overdos	Y	O
)	)	)	)	)	N	O
[	FW	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
(	(	(	(	(	N	O
2.4	CD	2.4	2.4	2.4	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

